Kidney Cancer Patient Centered Research

Patient Centered Research: The treatment landscape of RCC has evolved rapidly over the last decade increasing overall survival rates for patients. However, deciding which therapy to use is now a much more complex decision with more than four combination therapies approved in the first-line setting. As treatments have advanced, research into patient preferences to facilitate improved shared decision making has lagged. KCCure is leading the charge to close that gap. Our survey research is unparalleled, generating quantitative data to foster improvements in care by providing verifiable and analyzable data.

Since 2017, we have conducted 6 major surveys looking at a variety of questions. Our surveys have grown from 450 responses to our most recent survey that had over 1000 responses.

KCCure Research on Patient Anxiety Presented at ASCO 2018

KCCure Scientific Advisory Board Member Cris Bergerot presented findings from a KCCure survey related to anxiety for kidney cancer patients.  Our research found that patient anxiety rates are much higher than previously thought – with 70 percent of patient indicating anxiety levels that would necessitate pyscho-oncological support.  By an overwhelming majority, patients indicated that fear of recurrence was their biggest concern.

KCCure Presentation on Patient Views Related to Adjuvant Therapy

Until recently, no adjuvant therapy existed for treated localized RCC with a high risk of recurrence.  Last fall, the FDA approved the use of sunitinib in the adjuvant setting.  As a result, KCCure asked patients their views related to adjuvant therapy.  Our findings indicate that patients would wish to use adjuvant therapy based on an increase in disease free survival.  We also found that toxicity was less of a concern for patients and that efficacy was the most important factor in deciding whether or not engage in therapy.  This research was presented at ASCO-GU and also at the annual AUA (American Urological Association) meeting.

  1. Staehler M, Battle D, Bex A, Hammers H, George D. Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol. 2018.
  2. Bergerot C, Battle D, P B, Hammers H, Jonasch E, Derweesh I, et al. Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey. J Clin Oncol 2018;36 (suppl; abstr 4570).
  3. Battle D, Hammers H, Jonasch E, Derweesh I, George D, Ljungberg B, et al. PATIENTS PERSPECTIVES ON ADJUVANT THERAPY IN RENAL CELL CARCINOMA. The Journal of Urology. 2018;199, Issue 4, e875.
  4. Battle D, Hammers H, Jonasch E, Derweesh I, George D, Bex A, et al. Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma. J Clin Oncol 2018;36 (suppl; abstr 4571).
  5. Bergerot C., et al. (2018) “Distress in patients with renal cell carcinoma: A curious gap in knowledge.” BJU Int.

Lost Password


Subscribe for updates!